Tessera Therapeutics is pioneering Gene Writing™, a genome engineering technology that enables precise alterations to the human genome to treat genetic diseases at their source. This platform addresses the need for permanent and potentially curative therapies by delivering therapeutic genetic modifications directly to targeted tissues without the use of viral vectors.
Funding
$580M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BMFounders
Product
Problem
Many genetic diseases lack effective treatments because current gene therapies cannot precisely and permanently correct disease-causing mutations in a targeted manner. Existing methods often rely on viral vectors, which can have safety concerns and limited payload capacity, hindering their ability to address a wide range of genetic disorders.
Solution
Tessera Therapeutics is developing Gene Writing, a novel genome engineering technology designed to make precise alterations to the human genome for treating genetic diseases. This platform aims to provide permanent and potentially curative therapies by directly delivering therapeutic genetic modifications to targeted tissues without using viral vectors. Gene Writing is designed to make both small and large alterations to the genome. The company is also pioneering tissue-targeted non-viral delivery technology to ensure genomic alterations occur where needed.
Target Audience
The primary target audience includes patients with genetic diseases and the medical community seeking curative therapies.
Features
- Gene Writing technology for making precise alterations to the human genome
- Non-viral delivery methods for targeted tissue modification
- Ability to make both small and large alterations to the genome